Clinical Parkinsonism & Related Disorders

metrics 2024

Advancing knowledge on Parkinsonism and beyond.

Introduction

Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor1.90
Journal Impact Factor (5 years)-
H-Index-
Journal IF Without Self1.90
Eigen Factor0.00
Normal Eigen Factor0.16
Influence-
Immediacy Index0.60
Cited Half Life2.80
Citing Half Life8.20
JCI0.42
Total Documents-
WOS Total Citations315
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 178/277
Percentile 35.90
Quartile Q3

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 221/278
Percentile 20.50
Quartile Q4

Quartile History

Similar Journals

Degenerative Neurological and Neuromuscular Disease

Advancing knowledge in neurodegenerative research.
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

JOURNAL OF ASTHMA

Transforming insights into effective asthma treatments.
Publisher: TAYLOR & FRANCIS LTDISSN: 0277-0903Frequency: 12 issues/year

The Journal of Asthma, published by Taylor & Francis Ltd, stands as a prominent platform for disseminating crucial research in the fields of respiratory health, particularly focusing on asthma and related conditions. With an impact factor reflecting its esteemed position—ranking in the second and third quartiles of categories such as Immunology and Allergy, Medicine (miscellaneous), Pediatrics, and Pulmonary and Respiratory Medicine—the journal provides comprehensive insights into the latest findings and advancements in clinical practice and research. The journal, which has been in circulation since 1963, embraces a multidisciplinary approach, catering to a diverse audience that includes researchers, healthcare professionals, and students. Although it does not offer open access, it remains a critical resource for those seeking to deepen their understanding of asthma pathology and treatment strategies. The Journal of Asthma continues to serve as a vital academic forum, advancing knowledge and prompting innovation in the management of this pervasive health issue.

LUTS-Lower Urinary Tract Symptoms

Transforming understanding of urinary tract symptoms.
Publisher: WILEYISSN: 1757-5664Frequency: 6 issues/year

LUTS - Lower Urinary Tract Symptoms is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of urology and neurology with a special focus on lower urinary tract dysfunctions. Since its inception in 2010, the journal has established itself as an essential resource for researchers and practitioners, featuring cutting-edge research articles, reviews, and clinical studies that explore the complexities of lower urinary tract symptoms and their neurological implications. Housed in Japan, LUTS occupies an important niche in the academic landscape, currently ranked Q2 in Urology and Q3 in Neurology, and holding notable Scopus ranks within both fields. The journal serves as a platform for disseminating innovative ideas and fostering collaborative efforts among experts, making significant contributions to improve patient care and outcomes. With its commitment to high-quality scholarship, LUTS is an indispensable tool for those seeking to stay at the forefront of research in urology and neuroscience.

Neurodegenerative Disease Management

Bridging Research and Clinical Practice in Neurology
Publisher: FUTURE MEDICINE LTDISSN: 1758-2024Frequency: 6 issues/year

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

Current Neuropharmacology

Leading the way in neuroscience and therapeutic advancements.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Current Journal of Neurology

Exploring the complexities of the brain and beyond.
Publisher: TEHRAN UNIV MEDICAL SCIENCESISSN: 2717-011XFrequency: 4 issues/year

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

RHEUMATOLOGY INTERNATIONAL

Innovating clinical approaches for better patient care.
Publisher: SPRINGER HEIDELBERGISSN: 0172-8172Frequency: 12 issues/year

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Multiple Sclerosis International

Advancing knowledge, transforming lives in MS research.
Publisher: HINDAWI LTDISSN: 2090-2654Frequency:

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

Neurology and Clinical Neuroscience

Uniting specialists and practitioners in neurological advancements.
Publisher: WILEYISSN: 2049-4173Frequency: 6 issues/year

Neurology and Clinical Neuroscience, published by WILEY, is a pivotal peer-reviewed journal dedicated to advancing knowledge in the fields of neurology and clinical neuroscience. With an ISSN of 2049-4173, it encompasses a diverse range of topics related to neurological disorders, offering a platform for groundbreaking research and clinical practices. Although the journal does not currently operate under an open access model, it aims to foster an inclusive academic environment by providing high-quality content that is accessible to both specialists and general practitioners in the medical community. Despite its relatively recent establishment from 2013 to 2024, the journal has gained recognition with Scopus rankings highlighting its role in clinical neurology and neuroscience spheres. It serves as an essential resource for researchers, professionals, and students seeking to expand their understanding and engage in current discussions surrounding neurological health and diseases.

Epilepsy & Behavior Reports

Driving Forward the Dialogue on Epilepsy and Behavior
Publisher: ELSEVIER SCIENCE INCISSN: Frequency: 1 issue/year

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.